InflaRx Secures $150M Stock Offering to Fund Drug Development, Shares Surge
IFRX has more than doubled off its 52-week low of $0.711 on elevated volume (15× avg).
Summary
InflaRx announced a significant $150 million underwritten stock offering, intending to sell 75 million shares at $2 each, which is a discount to its current trading price. This substantial capital raise, representing approximately 75% of the company's current market capitalization, is critical as it directly addresses the material going concern warning issued in the company's recent Q1 2026 financial results. The proceeds are earmarked to advance pipeline activities, including the previously announced Phase 2 development of izicopan for ANCA-associated vasculitis, and provide liquidity through 2029. Despite the high dilution, the market reacted positively, with shares climbing 29%, indicating that traders view the secured funding as a vital step for the company's operational viability. Investors will now watch for the successful closing of the offering and the progress of the izicopan clinical trials.
At the time of this announcement, IFRX was trading at $2.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $0.71 to $2.86. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.